Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer

Código QR

Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer

Stephanie M Barrows,1 Kelly Wright,1 Catherine Copley-Merriman,1 James A Kaye,2 Marc Chioda,3 Robin Wiltshire,4 Knut Martin Torgersen,5 Elizabeth T Masters6 1Market Access and Outcomes Strategy, RTI Health Solutions, Ann Arbor, MI, USA; 2Epidemiology and Clinical Research, RTI Health Solutions, Walt...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Barrows SM, Wright K, Copley-Merriman C, Kaye JA, Chioda M, Wiltshire R, Torgersen KM, Masters ET
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	anaplastic lymphoma kinase ALK non–small cell lung cancer NSCLC carcinoma non–small cell lung Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/c973b3d4d18e4605a9596ed5a4aca270
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Clinical utility of liquid biopsy for the diagnosis and monitoring of EML4-ALK NSCLC patients
por: Sánchez-Herrero Estela, et al.
Publicado: (2020)

Clinicopathological and prognostic implications of ALK rearrangement in patients with completely surgically resected lung adenocarcinoma
por: Huan Zhang, et al.
Publicado: (2021)

ALK rearranged non–small cell lung carcinoma with EML4-NTRK3 fusion as a possible mechanism of resistance to third-generation ALK inhibitors
por: Elena Corral de la Fuente, et al.
Publicado: (2021)

Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives
por: Giroux Leprieur E, et al.
Publicado: (2016)

Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib
por: Jain RK, et al.
Publicado: (2017)

Defining Pathological Activities of ALK in Neuroblastoma, a Neural Crest-Derived Cancer
por: Anna M. Wulf, et al.
Publicado: (2021)

Different Therapeutic Strategies in 2 Young Patients with Advanced ALK-Rearranged Lung Adenocarcinoma: “The Light at the End of the Tunnel”
por: Umberto Caterino, et al.
Publicado: (2021)

Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations
por: Whitney E. Lewis, PharmD, et al.
Publicado: (2021)

Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors: a case of successful switch to an alternative ALK inhibitor and systematic review of the literature
por: Deng L, et al.
Publicado: (2018)

Clinical utility of ramucirumab in non-small-cell lung cancer
por: Uprety D
Publicado: (2019)

Efficacy and Safety of First-Line Treatment Strategies for Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis
por: Ling Peng, et al.
Publicado: (2021)

Identification and Validation of an Immune and Ferroptosis-Combined Index for Non–Small Cell Lung Cancer
por: Yang Teng, et al.
Publicado: (2021)

CYFRA 21-1 in patients with suspected cancer: evaluation of an optimal cutoff to assess the diagnostic efficacy and prognostic value
por: Garcia-Valdecasas Gayo Sonsoles, et al.
Publicado: (2020)

Safety of Surgery after Neoadjuvant Targeted Therapies in Non-Small Cell Lung Cancer: A Narrative Review
por: Tomasz Marjanski, et al.
Publicado: (2021)

Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report
por: Shuluan Li, et al.
Publicado: (2021)

Driver oncogenes in Sub-Saharan African patients with non-small cell lung cancer
por: Legius B, et al.
Publicado: (2016)

Efficacy and Drug Resistance Analysis of ALK Inhibitors in Combination with Stereotactic Body Radiation Therapy for Treating Lung Squamous Carcinoma Patient Harboring EML4-ALK Rearrangement
por: Liang L, et al.
Publicado: (2021)

Immunotherapy in patients with non-small cell lung cancer with ECOG PS 2
por: Damian Mojsak, et al.
Publicado: (2021)

Successful treatment of locally advanced lung cancer using late concurrent chemoradiation therapy administered after immune checkpoint inhibitor plus platinum chemotherapy
por: Taichi Matsubara, et al.
Publicado: (2021)

Association of expression and genotypes of thymidylate synthase in non-small cell lung cancer patients with different clinicopathological characteristics
por: Chen Jin-Yin, et al.
Publicado: (2021)

Adaptive Radiation Therapy in the Treatment of Lung Cancer: An Overview of the Current State of the Field
por: Huzaifa Piperdi, et al.
Publicado: (2021)

Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies
por: Gadgeel S, et al.
Publicado: (2019)

ANTIBODIES TO BENZO[A]PYRENE IN SERUM OF PATIENTS WITH NON-SMALL CELL LUNG CANCER
por: E. G. Polenok, et al.
Publicado: (2012)

<sup>1</sup>H HR-MAS NMR Based Metabolic Profiling of Lung Cancer Cells with Induced and De-Induced Cisplatin Resistance to Reveal Metabolic Resistance Adaptations
por: Martina Vermathen, et al.
Publicado: (2021)

Polo-like kinase 1 inhibition in NSCLC: mechanism of action and emerging predictive biomarkers
por: Stratmann JA, et al.
Publicado: (2019)

The Ki-67 Proliferation Index-Related Nomogram to Predict the Response of First-Line Tyrosine Kinase Inhibitors or Chemotherapy in Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor-Mutant Status
por: Weiguo Gu, et al.
Publicado: (2021)

Effect of antibiotic use on the efficacy of nivolumab in the treatment of advanced/metastatic non-small cell lung cancer: A meta-analysis
por: Huo Geng-wei, et al.
Publicado: (2021)

Research on the application of uniportal video-assisted thoracoscopic segmental resection of the lung in elderly patients with non-small cell lung cancer aged over 65 years
por: Hongya Xie, et al.
Publicado: (2021)

Postoperative Cardiac Ischemic Complications in Lung Cancer Patients
por: O. A. Bolshedvorskaya, et al.
Publicado: (2019)

Molecular genetic portrait of non-small cell lung cancer in Tambov region: regional experience
por: N. A. Ognerubov, et al.
Publicado: (2020)

New targeted treatments for non-small-cell lung cancer – role of nivolumab
por: Zago G, et al.
Publicado: (2016)

Small cell transformation of non‐small cell lung cancer under immunotherapy: Case series and literature review
por: Takuma Imakita, et al.
Publicado: (2021)

Cancer Stem Cell-Like Circulating Tumor Cells Are Prognostic in Non-Small Cell Lung Cancer
por: Eva Obermayr, et al.
Publicado: (2021)

Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China
por: Anwen Xiong, et al.
Publicado: (2021)

HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy
por: Gan J, et al.
Publicado: (2021)

Update Overview of the Role of Angiopoietins in Lung Cancer
por: Dimitris Tsakogiannis, et al.
Publicado: (2021)

Involvement of endothelial CK2 in the radiation induced perivascular resistant niche (PVRN) and the induction of radioresistance for non-small cell lung cancer (NSCLC) cells
por: Li,Qianwen, et al.
Publicado: (2019)

Hexokinases II‐mediated glycolysis governs susceptibility to crizotinib in ALK‐positive non‐small cell lung cancer
por: Caiyu Lin, et al.
Publicado: (2021)

Targeting RET-rearranged non-small-cell lung cancer: future prospects
por: Bronte G, et al.
Publicado: (2019)

First‐line nab‐paclitaxel plus carboplatin for patients with advanced non‐small cell lung cancer: Results of the NEPTUN study
por: Tobias Dechow, et al.
Publicado: (2021)